1-5 of 5
Nick R Anderson
Close
Sort by
Journal Articles

The Anti-Leprosy Agent Clofazimine Inhibits FLT3-ITD Mutant AML Stem Cells and Potently Enhances Effects of TKI

Harish Kumar, Andrew J. Paterson, Nick R Anderson, Shaowei Qiu, Sabyasachi Sanyal, Ravi Bhatia
Journal: Blood
Blood (2022) 140 (Supplement 1): 11533–11534.
https://doi.org/10.1182/blood-2022-169220
Published: 2022
Journal Articles

PRMT5 Inhibition Enhances Elimination of FLT3-ITD AML Stem Cells in Combination with TKI Treatment

Harish Kumar, Aditi Dhir, Andrew J. Paterson, Nick R Anderson, Shaowei Qiu, Xinyang Zhao, Rui Lu, Ravi Bhatia
Journal: Blood
Blood (2022) 140 (Supplement 1): 3073–3074.
https://doi.org/10.1182/blood-2022-168326
Published: 2022
Journal Articles

CXCL12 Knock-out Enhances Leukemia Stem Cell Response to Combination Chemotherapy Plus Tyrosine Kinase Inhibition in Flt3-ITD Acute Myeloid Leukemia

Nick R Anderson, BS, Hui Li, BS, Mason W Harris, Shaowei Qiu, MD, Amanda K Mullen, Andrew J Paterson, PhD, Ravi Bhatia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-142579
Published: 2020
Journal Articles

Identifying the Leukemia Stem Cell Niche Mediating Drug Resistance in Flt3-ITD Acute Myeloid Leukemia

Nick R Anderson, BS, Hui Li, BS, Mason W Harris, Shaowei Qiu, MD, Andrew J Paterson, PhD, Ravi Bhatia, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 909.
https://doi.org/10.1182/blood-2019-124379
Published: 2019
Journal Articles

An Epigenetic Screen Identifies PRMT5 As a Target for Inhibition of FLT3-ITD AML Cell Growth in Combination with Tyrosine Kinase Inhibitors

Aditi Dhir, MD, Andrew J Paterson, PhD, Shaowei Qiu, MD, Amanda K Mullen, Nick R Anderson, BS, Ravi Bhatia, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2524.
https://doi.org/10.1182/blood-2019-125178
Published: 2019